Guillain-barre syndrome drugs market was valued at $1.2 billion in 2025 and is projected to reach $2.2 billion by 2035, growing at a CAGR of 6.1% during the forecast period (2026-2035). Guillain-Barré Syndrome (GBS) is a rare, acute neuromuscular disorder characterized by an autoimmune-mediated attack on peripheral nerves, often triggered by a preceding infection in otherwise healthy individuals. The condition involves autoantibodies and activation of the classical complement pathway, leading to nerve inflammation and damage. Clinically, GBS progresses rapidly and may result in severe weakness, paralysis, and, in critical cases, respiratory failure requiring intensive care support. Due to its acute onset and narrow therapeutic window, early diagnosis and timely intervention are essential to improve patient outcomes. GBS leads to more than 22,000 hospitalizations annually across the US and Europe and affects an estimated 150,000 individuals globally each year. Despite its severity, there are currently no US FDA-approved disease modifying therapies specifically indicated for GBS.
Browse the full report description of “Guillain-Barre Syndrome Drugs Market Size, Share & Trends Analysis Report by Drug Class (Immunoglobulins (IVIG) and Corticosteroids), by Treatment Type (First-Line Treatment and Adjunctive or Supportive Treatment) and by Application (Hospital, Clinics and Other), Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/guillain-barre-syndrome-drugs-market
However ongoing efforts to develop targeted therapies reflect the increasing focus on addressing the underlying immune mechanisms responsible for nerve damage in this acute neuroinflammatory disorder. For instance, in January 2026, Annexon, Inc. announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart, an investigational monoclonal antibody targeting C1q, for the treatment of GBS. The submission is supported by results from a Phase 3 clinical study evaluating its impact on neuroinflammation and functional recovery. If approved, tanruprubart could represent the first targeted therapy specifically indicated for GBS. The regulatory review process is ongoing, and further interactions with global regulatory authorities are anticipated.
Market Coverage
Key questions addressed by the report.
Global Guillain-Barre Syndrome Drugs Market Report Segment
By Drug Class
By Application
Application
Global Guillain-Barre Syndrome Drugs Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/guillain-barre-syndrome-drugs-market